	US 11,986,479 B2
	Combination drug products for treating patients suffering from one or more medical conditions caused by coronavirus infection, including by SARS-CoV-2, its alpha, beta, delta, or omicron variants and sub variants
David M. Naeger, Gainesville, VA (US)
Assigned to PHARSOLN, INC., Arlington, VA (US)
Filed by PharSoln, Inc., Arlington, VA (US)
Filed on Feb. 15, 2023, as Appl. No. 18/110,238.
Claims priority of provisional application 63/413,045, filed on Oct. 4, 2022.
Claims priority of provisional application 63/391,414, filed on Jul. 22, 2022.
Prior Publication US 2024/0024329 A1, Jan. 25, 2024
Int. Cl. A61K 31/52 (2006.01); A61K 31/145 (2006.01); A61K 31/573 (2006.01); A61P 31/14 (2006.01)

CPC A61K 31/52 (2013.01) [A61K 31/145 (2013.01); A61K 31/573 (2013.01); A61P 31/14 (2018.01)]

9 Claims

1. A method of inhibiting viral replication in a human subject testing positive for a coronavirus infection, the method comprising administering to the human subject an oral daily dose of a combination drug product, wherein the oral daily dose comprises (i) a first dose of at least 375 mg of disulfiram and at least 75 mg of mercaptopurine or azathioprine, and (ii) a second dose of at least 250 mg of disulfiram and at least 50 mg of mercaptopurine or azathioprine.